A quality improvement project to increase compliance with indicated prechemotherapy pneumococcal vaccination.


218 Background: Severe pneumonia is associated with high morbidity and mortality in cancer patients. The most common pathogen is S. pneumoniae, responsible for 2/3 of pneumonia-related deaths. Current guidelines recommend routine use of 13-valent (Prevnar 13) and 23-valent (PPSV23) pneumococcal vaccine for immunocompromised patients (cancer patients). Of… (More)
DOI: 10.1200/jco.2016.34.7_suppl.218